News for Krystal Biotech, Inc. (KRYS)

**media[588445,588446]**

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

KRYS stock surges 15% in a month on strong uptake of Vyjuvek and encouraging pipeline progress. We are optimistic about the stock as we believe there is room for further growth.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Krystal Biotech (KRYS) has received a positive recommendation from EU regulators for its drug Vyjuvek for the treatment of wounds in patients with dystrophic epidermolysis bullosa.

Krystal Biotech Inc (KRYS), a commercial-stage biotechnology company, announced on February 28, 2025, that the European Medicines Agency's Committee for Medicin

EC approval decision anticipated in second quarter of 2025 PITTSBURGH, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the ”œCompany”) ( KRYS),

Summary Krystal Biotech Inc (KRYS), a commercial-stage biotechnology company, announced on February 26, 2025, that it will participate in the TD Cowen 45th Annu

PITTSBURGH, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the ”œCompany”) ( KRYS), a commercial-stage biotechnology company, today announced tha

Krystal Biotech (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Krystal Biotech (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

KRYS stock gains despite reporting mixed fourth-quarter results as lead drug Vyjuvek's launch in the United States shows strong uptake.

Discover key insights from Krystal Biotech's Q4 2024 earnings call, including VYJUVEK's robust growth, plans for EU/Japan launches, and a $1B sales target.

Krystal Biotech, Inc. (NASDAQ:KRYS) Q4 2024 Results Conference Call February 19, 2025 8:30 AM ETCompany ParticipantsStephane Paquette - VP, Corporate...

Krystal Biotech press release (KRYS): Q4 GAAP EPS of $1.58 beats by $0.39. Revenue of $91.1M (+116.4% Y/Y) misses by $0.25M. Cash, cash equivalents, and investments totaled $749.6M

**media[544261]**

Krystal Biotech Inc (KRYS) is set to release its Q4 2024 earnings on Feb 19, 2025. The consensus estimate for Q4 2024 revenue is $90.49 million, and the earning

On December 31, 2024, Redmile Group, LLC (Trades, Portfolio) executed a significant transaction involving Zymeworks Inc (ZYME), reducing its holdings by 261,448

On December 31, 2024, Redmile Group, LLC (Trades, Portfolio) made a notable acquisition by purchasing 7,197,951 shares of Silence Therapeutics PLC. This transac